Physician profile
William B Cherry
NPI 1366429730
$8,277.86
in general payments reported to CMS, 2019-2025
16 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,572 · 2020: $18.77 · 2022: $16.17 · 2023: $85.26 · 2024: $3,277 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $670.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,571.33 | 2019-2025 | Nucala |
| Gen-Probe, INC. | $3,000.00 | 2024 | None |
| Genzyme Corporation | $444.01 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $44.48 | 2025 | |
| Irhythm Technologies, INC. | $42.17 | 2024 | Zio Monitor, Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $34.82 | 2019-2020 | |
| Tolmar, INC. | $30.44 | 2023-2024 | |
| Tempus Ai, INC | $28.86 | 2024 | |
| Optinose US, INC. | $21.53 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.50 | 2023 | |
| Viiv Healthcare Company | $13.85 | 2024 | Cabenuva |
| Grifols USA, LLC | $13.64 | 2023 | Xembify |
| Lilly USA, LLC | $12.23 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.